<DOC>
	<DOCNO>NCT00091884</DOCNO>
	<brief_summary>Some patient HIV/AIDS suffer dangerous viral infection retina ( organ ) call cytomegalovirus infection ( CMV ) . The medication currently use treat CMV serious side effect . AIDS patient prone infection immune system produce low number CD4+T lymphocytes , type blood cell fight viral infection . Some new HIV medication strengthen immune system . This study investigate possibility CMV patient HIV medication develop immune system strong enough fight CMV without CMV medication . The study enroll maximum 15 adult HIV/AIDS patient CD4+T cell count 150 cells/microliter inactive CMV retinitis immediately sight threaten . It expect last approximately 2 year . Each prospective participant physical examination complete eye examination , include retina photograph , eye examination retina photograph repeat 2 week later . If evidence active CMV retinitis , participant enrol study , CMV medication stop . The participant physical eye examination every 2 week first 3 month study , every 3 week next 3 month . After 6 month , frequency examination 2-8 week , depend participant 's CD4 count . After one year , participant CD4 count remain 150 cells/microliter may return care local ophthalmologist HIV/CMV experience , revisit clinical center every 6 month . The participant 's CMV medication restart CMV retinitis become active , terminate participation study .</brief_summary>
	<brief_title>Efficacy Elevated CD4 Counts CMV Retinitis</brief_title>
	<detailed_description>This clinical trial determine whether elevated CD4 count result medication human immunodeficiency virus ( HIV ) effective control cytomegalovirus ( CMV ) retinitis . Patients non-progressive retinal disease consistent inactive CMV retinitis location immediately sight threaten , currently receive systemic maintenance therapy ganciclovir , foscarnet , cidofovir , total CD4 cell count great 150 cell per microliter anti-CMV therapy discontinue . Patients closely follow progression CMV retinitis . The primary endpoint study progression CMV retinitis . Secondary endpoint include occurrence extraocular CMV disease , morbidity , mortality , virologic data , HIV burden .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis AIDS define Centers Disease Control . Inactive , nonsightthreatening CMV retinitis . Non sightthreatening CMV retinitis define CMV retinitis within 1000 micron optic disc 1000 micron fovea . Exception : patient CMV retinitis within 1000 micron fovea disc one eye , visual acuity eye bad 20/400 without use eccentric fixation , visual acuity eye 20/400 good . CD4 T cell count great 150 cell per microliter . Patients must able understand nature study , agree provision , understand sign inform consent form . Women men age 18 old eligible enrollment . Platelets great 25,000/microliter . Hemoglobin great 8.5 gm . Total neutrophil count great 750/mm ( 3 ) . Karnofsky performance score great equal 60 . Receiving systemic antiCMV therapy . Receiving antiHIV therapy . If patient receive IL2 , least one month last infusion must elapse prior assessment eligibility . EXCLUSION CRITERIA : Intraocular sustain release ganciclovir implant eye le 9 month , organ involvement CMV infection require use systemic ganciclovir foscarnet . CMV retinitis involve retina solely anterior equator , within 1000 micron optic disc , within 1000 micron fovea . Exception : patient lesion involve fovea disc cause visual acuity bad 20/400 without use eccentric fixation , may include . Opacification cornea , lens , vitreous either eye precludes examination fundus . Other retinal disease could obscure diagnosis CMV retinitis , ocular toxoplasmosis . Significant psychiatric emotional disorder would impair patient understand participation trial . Life expectancy less three month . Active CMV disease require systemic antiCMV therapy . CMV retinitis first diagnosised CD4 Tcell count great 150 cell per microliter . Need medication antiCMV effect . Participation conflict clinical trial . Progression CMV retinitis screen baseline examination .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2005</verification_date>
	<keyword>HIV</keyword>
	<keyword>Immune Recovery</keyword>
	<keyword>Reactivation</keyword>
	<keyword>Anti-Viral Medication</keyword>
	<keyword>HAART</keyword>
	<keyword>CMV Retinitis</keyword>
	<keyword>Retinal Disease</keyword>
</DOC>